352 related articles for article (PubMed ID: 37468313)
41. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
McInnes IB; Szekanecz Z; McGonagle D; Maksymowych WP; Pfeil A; Lippe R; Song IH; Lertratanakul A; Sornasse T; Biljan A; Deodhar A
Rheumatology (Oxford); 2022 May; 61(5):1783-1794. PubMed ID: 34668515
[TBL] [Abstract][Full Text] [Related]
42. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
Alten R; Mischkewitz M; Stefanski AL; Dörner T
Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
[TBL] [Abstract][Full Text] [Related]
43. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
Angelini J; Talotta R; Roncato R; Fornasier G; Barbiero G; Dal Cin L; Brancati S; Scaglione F
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32635659
[TBL] [Abstract][Full Text] [Related]
44. JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis.
Crispino N; Ciccia F
Clin Exp Rheumatol; 2021; 39(3):668-675. PubMed ID: 33200731
[TBL] [Abstract][Full Text] [Related]
45. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
46. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
Singh S; Singh S
Int Immunopharmacol; 2020 Sep; 86():106731. PubMed ID: 32590315
[TBL] [Abstract][Full Text] [Related]
47. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Harigai M; Honda S
Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors.
Xiang J; Wang Y; Wang W; Yu J; Zheng L; Hong Y; Shi L; Zhang C; Chen N; Xu J; Gong X; Zhang Z; Cui H; Zhou Q; Zhang D; Liu Y; Ke Y; Shen J; Xia G; Bai X
Bioorg Chem; 2023 Nov; 140():106765. PubMed ID: 37582330
[TBL] [Abstract][Full Text] [Related]
49. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
[TBL] [Abstract][Full Text] [Related]
50. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
[TBL] [Abstract][Full Text] [Related]
51. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
[TBL] [Abstract][Full Text] [Related]
52. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
53. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
54. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
55. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
56. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE; McInnes IB; Siebert S
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
[TBL] [Abstract][Full Text] [Related]
57. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions.
Fragoulis GE; Brock J; Basu N; McInnes IB; Siebert S
J Allergy Clin Immunol; 2021 Oct; 148(4):941-952. PubMed ID: 34450118
[TBL] [Abstract][Full Text] [Related]
58. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
59. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract][Full Text] [Related]
60. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
Kotyla PJ; Islam MA; Engelmann M
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]